Effect of short, term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: An analysis from the International Bone Marrow Transplant Registry

Blood

Volumn 95, Issue 2, 2000, Pages 410-415

  Giralt, Sergio ^b   Szydlo, Richard ^b   Goldman, John M ^b   Veum Stone, Judy ^b   Biggs, James C ^b   Herzig, Roger H ^b   Klein, John P ^b   McGlave, Philip B ^b   Schiller, Gary ^b   Gale, Robert Peter ^b   Rowlings, Philip A ^b   Horowitz, Mary M ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA ANTIGEN; HYDROXYUREA; METHOTREXATE; RECOMBINANT ALPHA INTERFERON;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; SURVIVAL TIME; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CYCLOSPORINE; DISEASE-FREE SURVIVAL; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, CHRONIC; LIVING DONORS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR FAMILY; REGISTRIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 12944310971     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fefer A, Cheever MA, Thomas ED, et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation, and marrow transplantation from an identical twin. N Engl J Med. 1979;303:333-337.
2. Goldman JM, Apperley JF, Jones L, et al. Bone marrow transplantation tor patients with chronic myeloid leukemia. N Engl J Med. 1986;314:202-207.
3. Speck B, Bortin MM, Champlin R, et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984;1:665-668.
4. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1986;104:155-163.
5. Biggs JC, Szer J, Crilley P, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood. 1992;80:1352-1357.
6. Clift RA, Appelbaum FR, Thomas ED. Bone marrow transplantation for chronic myelogenous leukemia [letter]. Blood. 1992;83:2752.
7. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha Ain chronic myelogenous leukemia. N Engl J Med. 1986;314: 1065-1069.
8. Talpaz M, Kantarijian H, Kurzrock R, Trujillo J, Gutterman JU. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Ann Intern Med. 1991;114:532-538.
9. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
10. Hehlmann R, Heimpel H, Hasford J, et al, and the German CML Study Group. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994;84:4064-4067.
11. Allan NC, Richards SM, Shepherd PCA. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995;345:1392-1397.
12. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interteron alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst. 1997;89:1616-1620.
13. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interteron alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-229.
14. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691-703.
15. Kantarjian H, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood. 1996;87:3069-3081.
16. Goldman JM: Management of chronic myeloid leukaemia. Blood Rev. 1994;8:21-29.
17. Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med. 1998;127:1080-1088.
18. Lee SJ, Anasetti C, Horowitz MM, Antin J. Initial therapy for chronic myelogenous leukemia: playing the odds [edilorial]. J Clin Oncol. 1998;16: 2897-2903.
19. Gale RP, Hehlmann R, Zhang MJ, et al, and the German CML Study Group. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood. 1998;91:1810-1819.
20. Goldman JM, Szydlo R, Horowitz MM, et al, for the Advisory Committee of the IBMTR. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82:2235-2238.
21. Baron S, Trying SK, Fleischmann WR Jr, et al. The interferons: mechanisms of action and clinical applications. JAMA. 1991;266:1375-1383.
22. Giralt SA, Kantarjian HM, Talpaz M, et al. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993;11:1055-1061.
23. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood. 1995;85:2981-2990.
24. Beelen DW, Elmaagacli AH, Schaefer UW. The adverse influence of pretransplant interferon-α (IFN-α) on transplant outcome after marrow transplantation for chronic phase chronic myelogenous leukemia increases with the duration of IFN-α exposure [letter]. Blood. 1999;93:1779-1780.
25. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol. 1987;67:397-406.
26. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;75:2459-2464.
27. Klein JP, Moeschberger ML. Survival Analyses: Techniques for Censored and Truncated Data. New York, NY: Springer-Verlag; 1997.
28. Commenges D, Andersen PK. Score test of homogeneity for survival data. Lifetime Data Anal. 1995;1:145-156.
29. Hehlmann R, Kolb HJ, Berger U, Muth A, Hochhaus A, Ansari H. Influence of pretransplant treatment on survival after allogenous bone marrow transplantation in CML [abstract]. Blood. 1997; 90(suppl 1):228a.
30. Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant interieron-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood. 1998;92:394-401.